ArticleCureus2024
Initiation of Low-Dose Intravenous Buprenorphine for Opioid Use Disorder: A Case Series and Literature Review.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Opioid use disorder (OUD) remains a significant public health challenge with patients often facing barriers to initiating medications for opioid use disorder (MOUD). Traditional initiation methods for buprenorphine-naloxone (buprenorphine/naloxone) can be challenging due to the longer duration of transition and the risk of precipitated withdrawal. This manuscript presents a case series of four patients who successfully transitioned to buprenorphine/naloxone maintenance using a novel approach: low-dose intravenous (IV) buprenorphine initiation. These cases presented in the manuscript involved patients with dual diagnoses of OUD and difficult-to-treat pain. Intravenous buprenorphine was administered at a dose of 0.3 mg every half-hour, with a maximum of four doses. Patients' withdrawal symptoms were monitored using the Clinical Opioid Withdrawal Scale (COWS). Comfort medications were provided as needed. All four patients were successfully transitioned to sublingual (SL) buprenorphine/naloxone without experiencing precipitated withdrawal. Patients were discharged with follow-up appointments at buprenorphine/naloxone clinics and bridge supplies of buprenorphine/naloxone. Low-dose IV buprenorphine initiation offers a rapid and effective method for transitioning patients from full-agonist opioids (FAOs) to buprenorphine/naloxone without precipitated withdrawal. This approach has the potential to increase treatment retention and patient satisfaction. This case series highlights the success of low-dose IV buprenorphine initiation in patients with OUD and chronic pain. Further research is needed to standardize this approach and assess long-term outcomes. Initiating MOUD with this method may improve patient care and reduce the burden on the healthcare system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.